Basch EM, et al. - In men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, researchers assessed pain palliation as the primary endpoint for cabozantinib vs mitoxantrone-prednisone using patient-reported outcome measures. Study participants included men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with docetaxel and either abiraterone or enzalutamide. The intervention included cabozantinib 60 mg orally once a day vs mitoxantrone 12 mg/m²every 3 week plus 5 mg orally twice a day of prednisone. According to this randomized, double-blind phase 3 trial, cabozantinib treatment in heavily pretreated patients with mCRPC and symptomatic bone metastases showed no better palliation of pain than mitoxantrone-prednisone.